(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 December 2010 (23.12.2010)

PCT

(10) International Publication Number
WO 2010/146409 A3

(51) **International Patent Classification**:
A61K 9/14 (2006.01) *A61K 9/00* (2006.01)
A61K 9/51 (2006.01) *A61K 31/4184* (2006.01)

(21) **International Application Number**:
PCT/HU2010/000073

(22) **International Filing Date**:
18 June 2010 (18.06.2010)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
P0900376 19 June 2009 (19.06.2009) HU

(71) **Applicant** *(for all designated States except US)*: **NANGENEX, INC.** [HU/HU]; Záhony utca 7., H-1031 Budapest (HU).

(72) **Inventors; and**
(75) **Inventors/Applicants** *(for US only)*: **FILIPCSEI, Genovéva** [HU/HU]; Bajnok utca 15.I/9., H-1063 Budapest (HU). **ÖTVÖS, Zsolt** [HU/HU]; Raisio utca 4.I/2., H-6640 Csongrád (HU). **PONGRÁCZ, Katalin** [HU/HU]; Ady Endre út 23-25/C., H-Budapest (HU). **DARVAS, Ferenc** [HU/HU]; Lisznai utca 15., H-1016 Budapest (HU).

(74) **Common Representative**: **NANGENEX, INC.**; Záhony utca 7., H-1031 Budapest (HU).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) **Date of publication of the international search report**:
9 September 2011

WO 2010/146409 A3

(54) **Title**: NANOPARTICULATE CANDESARTAN CILEXETIL COMPOSITIONS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

(57) **Abstract**: The present invention is directed to nanostructured (nanoparticulated) Candesartan or its pharmaceutically acceptable ester, preferable Candesartan Cilexetil, or co-crystal compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Candesartan or its pharmaceutically acceptable ester, preferable Candesartan Cilexetil, or co-crystal according to the invention have an average particle size of less than about 500 nm. Candesartan Cilexetil is a prodrug, is hydrolyzed to Candesartan during absorption from the gastrointestinal tract. Candesartan is a selective AT1 subtype angiotensin II receptor antagonist.